Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Minerva Surgical, Inc. UTRS OTC

Other OTC • Healthcare • Medical - Healthcare Information Services • US • USD

SharesGrow Score
48/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$100.00
+99999900%

Minerva Surgical, Inc. (UTRS) is a Medical - Healthcare Information Services company in the Healthcare sector, currently trading at $0.00. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is UTRS = $100 (+99999900% upside).

Financials: revenue is $50M, +26.6%/yr average growth. Net income is $34M (loss), growing at -0.9%/yr. Net profit margin is -67.8% (negative). Gross margin is 54.2% (+8.8 pp trend).

Balance sheet: total debt is $40M against $17M equity (Debt-to-Equity (D/E) ratio 2.31, leveraged). Current ratio is 2.53 (strong liquidity). Debt-to-assets is 57.6%. Total assets: $69M.

Analyst outlook: 3 / 4 analysts rate UTRS as buy (75%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 50/100 (Partial), Future 85/100 (Pass), Income 10/100 (Fail).

$100.00
▲ 99999900% Upside
Average Price Target
The 12-month price target for Minerva Surgical, Inc. is $100.00.

UTRS SharesGrow Score Overview

56/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 85/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — UTRS

✓
VALUE Pass
100/100
UTRS trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $100, implying +99999900% from the current price $0. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
UTRS: +26.6%/yr revenue is, -0.9%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
33/100
Balance sheet UTRS: Debt-to-Equity (D/E) ratio 2.31 (leveraged), Current ratio is 2.53 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
50/100
UTRS: Gross margin is 54.2% (+8.8 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
85/100
Analyst outlook: 3 / 4 analysts rate UTRS as buy (75%). Analyst consensus target is $100 (+99999900% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
UTRS: Net profit margin is -67.8%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.00001-0.001
Volume500
Avg Volume (30D)1
Market Cap$888.00
Beta (1Y)4.60
Share Statistics
EPS (TTM)-23.68
Shares Outstanding$1.44M
IPO Date2021-10-22
Employees174
CEODarin Hammers
Financial Highlights & Ratios
Revenue (TTM)$50.29M
Gross Profit$27.24M
EBITDA$-20.07M
Net Income$-34.11M
Operating Income$-30.9M
Total Cash$6.94M
Total Debt$39.69M
Net Debt$32.75M
Total Assets$68.9M
Price / Earnings (P/E)-0
Price / Sales (P/S)0
Analyst Forecast
1Y Price Target$100.00
Target High$100.00
Target Low$100.00
Upside+99,999,900.0%
Rating ConsensusBuy
Analysts Covering4
Buy 75% Hold 0% Sell 25%
Company Info
CountryUS
ExchangeOther OTC
CurrencyUSD
ISINUS60343F2056

Price Chart

Track all markets on TradingView
UTRS
Minerva Surgical, Inc. ↗  ·  Other OTC
Healthcare • Medical - Healthcare Information Services
0.00 52WK RANGE 0.00

People Also View

RNAZ
RNAZ
TransCode Therapeutics, Inc.
$8.90
+1.14%
 HILS
HILS
Hillstream BioPharma, Inc.
$0.24
+5.66%
 SQL
SQL
SeqLL Inc.
$6.60
-2.38%
 DRMA
DRMA
Dermata Therapeutics, Inc.
$1.25
-3.85%
 AKAN
AKAN
Akanda Corp.
$3.13
-0.95%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message